ISSN 2515-8260 Volume 9, Issue 7, Summer 2022

Analysis of Precision Oncology for Pediatric Medicine: Past, Present and Future

Owis Ahmad Mustafa Khater[1], Maha Saleh Yousef Obeidat [2]

[1*]Pediatric Consultant, Primary health care corporation, Doha, Qatar
[2]Pediatric Consultant, Sama Pediatric Clinic, Amman, Jordan

*Owiskhater@yahoo.com, Maha_7_82@yahoo.com

Abstract

The biggest cause of non-accidental mortality in children and teens is childhood leukemia. Long-term life expectancies have increased over the past 50 years due to the introduction of new medicines and advancements in postoperative therapy. Nonetheless, among those who have survived leukemia, there is still significant morbidity related to cancer therapy and the prognosis for those whose recurrence is still dismal. The advent of molecular diagnostics, a method that tailors a person's treatment by using knowledge of a disease's genetic and biochemical profiles (as made possible after the next genotyping), has already begun to alter the therapy and diagnostic environment of pediatric cancer. Its application has led to advances in tumor categorization algorithms, a greater understanding of malignant transformation, and the development of physically and molecularly tailored therapy approaches. Precision oncologic oncology is a new method of treating cancer that has lately made significant advancements in reliable clinical practice. Recent developments in precision medicine that may examine the genetic variations of each tumor have high levels of engagement and added new cancer treatment options. The advent of this next-generation sequenced (NGS) has substantially aided our comprehension of pediatric cancer and revealed novel therapeutic options, even though a broad range of molecular techniques can examine malignancies. Compared to adult cancers, pediatric malignancies have a unique genetic makeup and fewer targets that can be targeted. However, the survival rate of patients with leukemia and solid tumors has significantly increased in the pediatric population because of precision oncology. This study examines the state of pediatric personalized oncology today and the clinical situations that can be applied easily. This also includes clinical studies evaluating the diagnostic value of therapeutic applications aligned to genetic abnormalities discovered by tumor screening and explains the latest innovations and different obstacles in personalized medicine for pediatric malignancies.

Keywords: Precision Oncology; Pediatric Medicine; Basket Trial; Umbrella Trial

Introduction

As a result of risk assessment, intensified cytotoxic chemotherapy, and multimodality available treatments, the prognosis for cancer-related children, has significantly improved over the past 50 years. All cancer patients must continue to see their outcomes improved, with a focus on boosting survival for those with an improper diagnosis and lowering severe

delayed adverse results from diagnostic imaging treatments. To include targeted medicines in medical studies and, eventually, the routine of treatment modality, the current study concentrates on the methodology used in pediatric oncology to examine the malignancy genomes. The ultimate objective of personalized medicine in pediatric oncology is the same as in other fields: to cure additional patients while reducing current therapies' immediate and lasting adverse reactions. Succeeding genomics has been used as one of the basic considerations in characterizing the genomic properties among the most prevalent pediatric cancer diagnosis over the past ten years [1]. The National Cancer Institute (NCI) Childhood Cancer Genomics Gaps assessed the completed generation sequence research. Despite ongoing advancements in extensive detection sequencing initiatives for pediatric cancers, the preponderance of pediatric childhood cancers has only a few tumor-normal pairs that have undergone thorough analysis. Therefore, these finding sequence alignment studies are insufficiently controlled to exclude recurrent mutations, which can occur with a frequency as high as 5–10% of occurrences for most illnesses.

Additionally, few samples from the residual disease have already been processed, and the genomes of many rare pediatric cancer forms have yet to be sufficiently explored. Successful genome sequence research has discovered significant facets of pediatric cancer genomes. Pediatric tumors contain significantly fewer mutations per similar DNA information than adult cancers. Important genomic processes of malignant transformation in juvenile malignancies include segmentation, chromosomal alterations, gene fusions, and abnormalities in genes affecting the epigenome [2]. Furthermore, all of these findings, research findings using discovery sequence data, have advanced the molecular categorization of some illnesses, identifying high-risk genomic functionalities linked to prediction and helping to stratify psychotherapy for several prevalent pediatric leukemias like leukemia and by its terms. However, the feasibility of routinely doing genomic profiling in the hospital nor the capacity to explore and understand specific patient-level sequence alignment information that will guide strategies for patient care and clinical trial enrollment are evaluated by exploratory sequencing research. These concerns need clinical sequencing investigations, in which the sequencing findings are typically given after the testing is completed in a laboratory environment. The concluded clinical sequenced studies, which involved kids and teens with relapsing, resistant, or high-risk solid tumors, showed that clinical decoding could be done at one location or across several locations with the help of a centralized facility. Even when clinical materials were used for genotyping, there was a great technical best performance.

Additionally, procedures for providing treatment professionals and care managers with results of tests, frequently involving germline testing, have been formed. An evaluation of how patients and clinicians see tumor characterization and germline decoding is starting to occur [3]. The percentages of potentially valuable variations (20–60%) were similar across the various genotyping equipment used in each investigation. When evaluated, only a small percentage of participants (2–8% of the studied groups) in these early studies got focused medication matched to a found actionable variation. This is not unexpected given that the study's limited clinical follow-up period and design prevent investigation of the effect of receiving matching precision medicine on mortality. Nonetheless, these preliminary clinical

sequencer investigations laid the groundwork for later specificity clinical testing to evaluate the effectiveness of mechanistically tailored treatments for pediatric cancer [4].

Overview of Precision medicine

Oncology probably stands at the forefront, even if genetic testing will undoubtedly penetrate many disorders (both malignant and noncancer). The notion that carcinoma is a genomic illness is one clear factor in this. Most malignancies have a combination of gene mutations and growth arrest that are transformed (and altered) and collaborate to define the biological mechanism that results in cancer origination and development. The growth of global initiatives to define the chromosomes of numerous cases encompassing virtually all important types of cancers has greatly aided oncology studies and has become more pliable for sophisticated clinical diagnosis. [5]. Oncologist has provided a staging ground for the generation sequencing framework that is distinct among surgical fields and the growing catalog of specific anticancer drugs under biomedical studies or commercial use. Fundamentally, the execution of generation sequencing therapeutic strategies may appear simple: first, characterize the tumor genome sequences of patient populations using the cutting-edge latest technology; third, funnel the sequence information through a base of knowledge of current and new chemotherapeutic agents; and third, provide the treating oncologist with a manually labeled list that can be implemented into making clinical decisions. To achieve this lofty objective, however, several issues must be resolved. To commence with, excellent power genomic data must be gathered from low volumes of normal archival tissues in the therapeutic situation. Few publications discuss the amazing innovative technologies that make massive amounts of genetic data practical in a therapeutic environment [6]. Despite the ongoing concerns about the amount of genomic data required, the pricing of numerous channels, and how quickly diagnostic genomic data can be conveyed, it is evident that the genetic code categorization existing technologies in use are developing rapidly to be capable of meeting the demands of personalized treatment. The difficulties with analysis that come with complete genomic information have been more difficult. The significance is clinical enough that driver changes must be differentiated from the significantly broader set of passenger modifications expressed in tumor DNA to accurately identify the germline and somatic modifications pertinent to each malignancy. Without computer algorithms to facilitate clinical-grade analysis, a thorough study and astute therapeutic perception of complete genetic data are unattainable. Although many areas of clinical molecular modeling are still in their childhood, many tools and strategies have already been developed that may help physicians prepare for the enormous influx of tumor and primordial genetic data [7].

Precision medicine and pediatric oncology

Various approaches can be used for molecule sensitivity measurement. It is possible to carry out whole-exome, whole-genome, and DNA fingerprinting alone or in conjunction with epigenomics and transcriptional microarray analyses. Identifying pediatric primary central nervous system cancers are increasingly included in DNA methylation-based molecular diagnostics. Directed genotyping panels depending on genes are becoming more and more

common in clinical settings and are also widely viable. Contrary to WGS or WES investigations, work on behalf has a better chance of detecting low-level clonal mutations within a tumor. It is essential to determine patient categories which might benefit so much from molecularly personalized medicine and quicker creation of novel medications for initial stage medical studies, even if full genetic testing has now been urged for all pediatric malignancies.



Flowchart depicting the efficient use of sequencing in pediatric oncology reproduced with permission from [8].

Past and present studies in pediatric oncology

Most malignancies contain somatic gene mutations, variations, or combinations that NGS can identify in systems that have received clinical approval. 90% of the 440 adult cancer sufferers analyzed in a recent genomic study had to have at minimum one targetable or responsive mutation in their tumor. Precision chemotherapy is a field of study that is very prominent in the patient group, with efforts concentrated on creating targeted medicines for individuals who cannot be cured by conventional medicine. Presently, nevertheless, contrasted to the discipline of personalized treatment for tumors of adult origin, the applicability of biomolecule treatments in children is somewhat constrained. Leukemia has seen several developments in pediatric personalized treatment thus far, compared to solid malignancies. Instead of being brought on by environmental exposure, pediatric cancers are significantly more frequently caused by hereditary or random abnormalities in maturation. From the perspective of germline mutations and the types of changed genes, the chromosomal topography of modifications in juvenile malignancy thus demonstrates notable variations from adult tumors. With rare exceptions, juvenile tumors have a lower gene mutation

frequency and significantly fewer minor indels and single nucleotide variations (SNVs). In contrast, juvenile cancers display great specificity of relationships with histologic tumor subtypes and have a considerably large incidence of particular restructuring (such as gene fusions and chromosomal aberrations). Most genetic modifications in pediatric leukemias and solid tumors encompass well-known genetic material and oncogenesis corridors, including the multiplication of other gene mutations. [9].

Trails in precision medicine

Refractory and relapsed cancer among multiple histologies - Basket trails

The rapid advancements in functional genomics, our knowledge of the genome sequence model, and the accessibility of targeted treatments must all be considered when designing precision oncology studies. Another element that might be linked to unexpected developments is the regulatory system. Personalized oncologist trial designs, primarily created in the domain of malignant tumors, are undergoing an ongoing transformation due to such and other reasons. To emphasize the crucial components of precision medicine study development pertinent to pediatric oncology, we show details of some pediatric cancer personalized cancer trials. The most comprehensive accuracy trials are alluded to as "basket trials." Genotyping outcomes are utilized to discover responsive variations associated with qualification for ongoing clinical arms of targeted therapies across various cancer illnesses in these programs. When genetic variations that could anticipate responsiveness to a precision medicine of significance appear at either a modest or undetermined prevalence across conditions, a basket experiment is the best research design [10]. Basket trials are essential for discovering targeted medicines in pediatric oncology due to our insufficient understanding of the number of genetic variations and their carcinogenic propensity in several pediatric malignancies. Substantial basket trial programs for adolescents and children with relapsed or refractory pediatric malignancies are currently under place in the United States and Europe. Registration is open to kids and teenagers aged 1 to 21 with non-Hodgkin lymphomas, solid tumors reoccurring or resistant to treatment, or histiocytosis. Except for diffuse fundamental pontine glioma, which allows a confirmatory biopsy, a sampling of the participants' recurrent tumor is sent for decoding using an assay created especially for the MATCH experiment. The sequenced system utilizes dual primer multiplexing RNA-based PCR for fusion identification and amplicon technologies for mutant identification.

Sequenced data is examined to ascertain whether such a relevant operational alteration is present. Each study arm has a set of identified exploitable alterations of interest. Presently, there are seven therapeutic arms, and more are anticipated to start operating in the future [11]. Suppose there is current data from a clinical study relating gene variations to responsiveness to the focused medication. In that case, the treatment groups are chosen for participation in the pediatric COG-NCI Paediatric Matching. There must also be experimental preclinical research demonstrating that the gene variations are a factor in the success of responsiveness to precision medicine for potential therapeutic modalities when current studies are absent or sparse, such as case studies. Notably, the basket trial tests the assumption that the biomarkers will predict responsiveness to precision medicine independently of the kind of cancer. Hence the current studies used need not originate from the same disease type. The cancer treatment

studies are open to youngsters and teenagers ages 0 to 18 with solid tumors or leukemias that have relapsed or are no longer responding to treatment. Within one of the active clinical genotyping studies in Europe, such as multicentric, possible future real evidence study Molecular Profiling for Pediatric and Young Adult Cancer Therapy Categorization or Individualized therapy for Relapsed Leukemias, clients had to have a molecular genetic characterization of their reoccurring or refractory tumor accomplished. In most of these therapeutic genomics research in Europe, specimens are sequenced using different platforms, such as the good exome, RNA, and functional genomics. To ascertain whether the relevant variation is available and if the functional variant complements one of the SMART intervention groups or other targeting agent trials, genotyping data are evaluated and analyzed at a heterogeneous biological tumor board. SMART now includes five genetic goals and monitors and seven therapeutic arms. Stage 1 dose progression and two enlargement phases are included in every therapeutic arm's autonomous clinical trial. As a result, six to 38 individuals will be enrolled in each arm.

In contrast to the Pediatric MATCH study, numerous treatment modalities combine one effective therapy drug with just another aimed agent or traditional cytotoxic treatments. Through an enriched technique, the study aims to investigate the function of vaguely understood structural abnormalities about their responsiveness to the intended medication and very well indicators. Each architecture has particular advantages and disadvantages. Therefore, initiatives to assess findings will produce new insights valuable to guide the development of future basket trials in pediatric oncology, especially if fundamental clinical and sequenced data are communicated across hemispheres [12].

Specific umbrella trials for relapsed disease

A basket study with a unique diagnostic is referred to as an umbrella trial. Whenever earlier discovery sequenced has provided a reasonable grasp of the genuinely valuable alterations present in a certain diagnostic and the prevalence of such variations is significant enough that research focused solely on that condition is achievable, an umbrella design may be desirable. It is not unexpected that neuroblastoma and leukemia are pediatric malignancies where a disproportionately high number of tumors-normal couples submitted to rediscovery decoding are now undergoing umbrella studies in relapsing illness. Philadelphia autosomes (Ph-like), a chromosomal subtype found in around 15% of adolescents, teenagers, and early adulthood and linked with a noticeably worse prognosis, was discovered and characterized as a result of rediscovery sequenced investigations in acute lymphoblastic leukemia (ALL). Ph-like ALL is distinguished from BCR-ABL rearrangement-positive leukemia by the occurrence of a signaling cascade expression profile, but there is no BCR-ABL fusion. Ph-like ALLs contain gene variations, such as alterations comprising ABL1/2, CSF1R, PDGFRB, translocations and mutation in CRLF2, JAK2, and EPOR, that stimulate phosphatase or cytokine signaling. Preclinical research and case research showed susceptibility to tyrosine phosphatase inhibitors or JAK inhibitors as precision medicine. Inhibitory processes cancer treatment is being combined either with ruxolitinib, a Jak inhibitor or adalimumab, an Abl/Src kinase inhibitor, depending on the gene mutations discovered, in a single organization trial currently enrolled service users 10 years of older people with refractory or recurrent ALL and

substantiation of CRLF2 hopefulness by flow cytometry [13]. It is noteworthy that adolescents 10 and older are enrolled in this biomarker-driven stage two study right from the start of the investigation. Recent remarks from the US Food and Drug Administration (FDA) and a cross-response team, which included the American Society of Clinical Oncology, backed such a method, in which entry requirements are broadened to enable patients to participate in early phase studies. Roughly 10% of over-expressionists have an ALK mutation. A greater rate of ALK alterations of about 25% at recurrence has been discovered using decoding of coupled baseline and relapsing samples. Eight targeting drugs were tested in-vitro on 17 well-characterized pediatric neuroblastoma-derived cell cultures. It was discovered that ALK-mutated cell lines were sensitive to the conjunction of the CDK4 blocker ribociclib and the ALK anticoagulant ceritinib. The Next Generations Customized Neuroblastoma Treatments study was created using this and other experimental data. For ages 1 to 21, individuals with refractory or relapsed glioblastoma are considered. Deep decoding is used to analyze tumors by biopsy and find ALK or RAS-MAPK pathway alterations. Ceritinib and ribociclib are given to individuals whose tumors contain mutations in the ALK network. In contrast, trametinib is given to individuals with tumors with mutations in the RAS-MAPK system. Subjects are included in the second therapy group and given HDM201, an oral HDM2 antagonist if they have adventurous TP53 and neither an ALK nor RAS/MAPK network change [14].

Advanced cancers and targeted therapy

Our knowledge of the genomes and the action of targeted medicines in pediatric malignancies is being improved by initial phase studies of a targetable drug when qualifying criteria also provide a genetic indicator. These studies frequently involve medications created specifically for gene variations found among the more prevalent malignant tumors and are frequently funded by the pharmaceutical sector. In the past, this kind of pediatric earliest stages research was frequently carried out several decades after the treatment was beneficial in malignant tumors with the right biomarkers. In other circumstances, pediatric patients with tumors without the necessary diagnostic marker were included. The BRAF blocker vemurafenib is one instance of developmental delays in pediatric cancers. The FDA authorized Vemurafenib in 2011 for the therapy of advanced or incurable melanoma with BRAF V600E variants. The first clinical study of vemurafenib in pediatric patients with recurrent or resistant BRAF-mutant gliomas didn't begin until 2015, despite reports that some pediatric gliomas carried the BRAF V600E gene in 2010 [15].

It should be noted that trials for the MEK antagonist selumetinib and the BRAF V600E agent dabrafenib were started before this. The phase II trial of an ALK antagonist crizotinib in pediatric individuals with refractory solid tumors or anaplastic large-cell carcinoma illustrates a phase ii study of a focused medication including pediatric patients with biomarkers affirmative and diagnostic uncertain. The research included multiple configurations: a dosage-escalation portion for all people (just without known ALK biomarker) to establish the highest dose that could be administered, an extended sample of patients with a diagnosis of ALK variations, and an additional cohort of individuals with neuroblastoma. The outcomes of this stage 1/2 experiment show the potential and difficulties of employing this study protocol

to develop precision medicine for pediatric cancers. Anaplastic large-cell carcinoma and aggressive myofibroblastic tumors bearing ALK hybrids demonstrated significant and long-lasting cures.

Given that only a portion of the recruited neurotoxicity individuals had ALK variations. Because the ALK mutations occurring in neuroblastoma are distinct from those prevalent in lung cancer, the illness by which crizotinib was developed, there were mixed outcomes in the neuroblastoma population. Recent efforts have been made to start targeted therapy early phase studies in pediatrics sooner in the commercial design phase. The preliminary trial of the Trk antagonist larotrectinib for TRK fusion-negative cancers is one notably notable instance. A previous presentation of preliminary information from larotrectinib phase 1 studies in patients with advanced disease revealed an objective RR of 91%. Individuals with tumors devoid of TRK fusions showed no reactions [16].

Disease-specific precision trials in newly diagnosed patients

Increasing cancer cure rates and reducing cancer toxicity treatment are molecular diagnostics' ultimate goals. This won't be possible until clinical genomics for more precise risk assessment and as a sign to use matching precision medicine in upfront management programs have been included in conventional treatment for individuals diagnosed. As with umbrella trials, knowledge of the gene variations expected to be found in a particular diagnosis is necessary for specificity trials in individuals diagnosed. Additionally, there must be proof relating illnesses' gene variations to the prognostic and/or efficacy of directed medicines. Leukemia specimens from individuals with newly discovered ALL are being profiled across several trials to check for the existence of the Ph-like transcriptional signature and/or Ph-like ALL-related mutations. In these trials, the effects of regular ALL treatments combined with therapies for Philadelphia-like leukemias with kine mutations or BCR-ABL positivity and JAK markers for leukemias with JAK/STAT changes are being assessed. Massive sequencing efforts have identified four unique molecular groupings in medulloblastoma, with huge ramifications for prognosis and therapy. For health risk assessment and therapy distribution in medical studies for individuals with recently diagnosed medulloblastoma, upfront molecular analysis is currently being used. St. Jude's research is currently examining whether the positive results reported in the WNT molecular subpopulation can be sustained with less medication in patients with a diagnosed medulloblastoma. To see if adding an SHH blocker after traditional cytotoxic treatment enhances outcomes in patients with medulloblastoma with the modified sonic hedgehog (SHH) pathways. It's important to note one characteristic that precision experiments with clinically diagnosed pediatric cancer patients all have. All be using a single-arm methodology rather than a randomized design due to the limited size of the genomically determined population chosen for treatments. In other circumstances, a comparison to a historic demographic will be used to estimate the result of the intervention on the genomically defined patient population. For undiagnosed pediatric oncology patients, the inability to carry out randomized studies is usually a problem, and techniques to deal with potential difficulties when assessing the data of solitary trials are expected to be required [17].

ISSN 2515-8260 Volume 9, Issue 7, Summer 2022

Prospects

Early highly detailed cancer studies have emphasized cancer diversity and chromosomal intricacy, along with the role(s) of epigenetic modifiers in influencing tumor prognosis and have enhanced our comprehension of cancer progression during the treatment process. According to NGS, numerous malignancies have mutations in the genes responsible for regulating gene expression. Numerous juvenile malignancies, notably leukemias, frequently display epigenetic and translational dysregulation. Personalized medicine may offer opportunities for chromatin alteration and transcribed program suppression. Engineered lethality, a form of immunotherapy that simultaneously disrupts genetic factors, is developing as a novel method of precise targeting. This is predicated on the idea that sequential targeting of two distinct and unconnected genes makes malignancies with poor prognoses and impairment alterations "preventable." Due to the changed gene expression patterns of epigenetic modifiers and genes responsible for DNA repair in cancer cells in contrast to normal cells, these genes are appealing targets for treatments. By specifically eradicating cancer cells, certain control genes could be targeted. Utilizing nanomaterials to combat cancer cells' susceptibility to therapy is another promising and cutting-edge application of precision medicine. Nanoparticle-based delivery technology improves the absorption of anticancer drugs and their targeted intracellular concentration in cancer cells. Versatile nanoparticles make it easier to customize treatment plans and distribute medication formulations for combinatorial treatments. Individualized medical care is more successful when using superparamagnetic iron oxide nanoparticles (SPIONs), which exhibit exceptional tumor-targeting efficacy and possess magnetization. Therefore, the integration of standard or specialized therapy with nanomaterials is the best example of customized medicine and may ultimately lead to eradicating and eliminating malignancy.

Recent advances in chemotherapy have included using antibodies against monoclonal antibodies and activation of the patient's immune response to fight cancer cells. Numerous immunotherapy treatments are utilized or researched for critical illness. For pediatric AML patients, gemtuzumab ozogamicin was becoming a standard therapy component. An anti-GD2 antibody called rituximab is used to treat glioblastoma. Immunotherapies (such as ganitumab), specific antibodies related compounds (such as brentuximab vedotin), bispecific T-cell engagers (such as blinatumomab), immunological immune modulatory (such as nivolumab, pembrolizumab, and ipilimumab), and anticancer immunizations are among the other immune checkpoint inhibitors being researched. T-cells that have undergone modifications have also been extensively used in cellular treatments. T cells are modified with recombinant antigen receptors (CAR) intended for prolonged multiplication and precise treatment of tumor cells because of their amazing capacity to detect foreign proteins from self-antigens using their sensors.

Through chimeric antibodies targeting CD19, CAR-T's new treatment has proved surprisingly effective in treating individuals with advanced, refractory B cell tumors. The effectiveness of CAR-T cell therapy in treating leukemia has been generalized to solid tumors, whereby sporadically published studies have shown some degree of minimal success. In a few clinical studies, GD2-specific CAR-T cells for neuroblastoma and the human epidermal growth factor receptor 2 (HER2) in oncocytoma have yielded unspectacular

results. Securing selectivity for addressing tumor cells while preserving healthy tissue and reducing mortality is a significant hurdle in CAR design. Other significant obstacles must be removed for CAR-T treatment to become more effective. Among the steps to ensure the successful execution of modified T-cells to the tumor cells include lowering physical barriers in the extracellular environment and removing the impact of inflammatory surroundings. Though CAR-T therapy has a great chance of treating solid tumors more effectively, these obstacles need to be solved [18].

Conclusion

There are currently several specificity experiments emerging for children diagnosed with cancer thanks to developments in molecular diagnostics in pediatric oncology during the past ten years. Our knowledge of the therapeutic effects of customized medicines will be enhanced by the initial batch of pediatric accuracy oncology trials. Additional comprehension of the pediatric cancer genome and scientific advances will result from inferential biology and medicine integrated into these highly precise trials (such as initiatives to use cell-free DNA lab tests for detecting genetic mutations) and communicating of actual results diagnostic and genotyping relevant data for ancillary analyses. Furthermore, more prospects for personalized treatment in pediatric tumors are likely to emerge through ongoing medication development, genome genotyping, and translational biological research.

References

1. Smith, M. A.; Seibel, N. L.; Altekruse, S. F.; Ries, L. A. G.; Melbert, D. L.; O'Leary, M.; Smith, F. O.; Reaman, G. H. Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century. JCO 2010, 28 (15), 2625–2634. https://doi.org/10.1200/JCO.2009.27.0421.
2. Elmore, L. W.; Greer, S. F.; Daniels, E. C.; Saxe, C. C.; Milner, M. H.; Krawiec, G. M.; Cance, W. G.; Phelps, W. C. Blueprint for Cancer Research: Critical Gaps and Opportunities. CA A Cancer J. Clin. 2021, 71 (2), 107–139. https://doi.org/10.3322/caac.21652.
3. Hunger, S. P.; Mullighan, C. G. Redefining ALL Classification: Detecting High-Risk ALL and Implementing Precision Medicine. Blood 2015, 125 (26), 3977–3987. https://doi.org/10.1182/blood-2015-02-580043.
4. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gautier-Foster, J.; Grody, W. W.; Hegde, M.; Lyon, E.; Spector, E.; Voelkerding, K.; Rehm, H. L.; ACMG Laboratory Quality Assurance Committee. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015, 17 (5), 405–424. https://doi.org/10.1038/gim.2015.30.
5. Furuta, E.; Okuda, H.; Kobayashi, A.; Watabe, K. Metabolic Genes in Cancer: Their Roles in Tumor Progression and Clinical Implications. Biochim Biophys Acta 2010, 1805 (2), 141–152. https://doi.org/10.1016/j.bbcan.2010.01.005.

6. Horak, P.; Fröhling, S.; Glimm, H. Integrating Next-Generation Sequencing into Clinical Oncology: Strategies, Promises and Pitfalls. ESMO Open 2016, 1 (5), e000094. https://doi.org/10.1136/esmoopen-2016-000094.
7. Horton, R. H.; Lucassen, A. M. Recent Developments in Genetic/Genomic Medicine. Clin Sci (Lond) 2019, 133 (5), 697–708. https://doi.org/10.1042/CS20180436.
8. Ahmed, A.; Vundamati, D.; Farooqi, M.; Guest, E. Precision Medicine in Pediatric Cancer: Current Applications and Future Prospects. High-Throughput 2018, 7 (4), 39. https://doi.org/10.3390/ht7040039.
9. Rahal, Z.; Abdulhai, F.; Kadara, H.; Saab, R. Genomics of Adult and Pediatric Solid Tumors. Am J Cancer Res 2018, 8 (8), 1356–1386.
10. Fountzilas, E.; Tsimberidou, A. M.; Vo, H. H.; Kurzrock, R. Clinical Trial Design in the Era of Precision Medicine. Genome Med 2022, 14 (1), 101. https://doi.org/10.1186/s13073-022-01102-1.
11. Laetsch, T. W.; DuBois, S. G.; Bender, J. G.; Macy, M. E.; Moreno, L. Opportunities and Challenges in Drug Development for Pediatric Cancers. Cancer Discov 2021, 11 (3), 545–559. https://doi.org/10.1158/2159-8290.CD-20-0779.
12. Chen, A. P.; Eljanne, M.; Harris, L.; Malik, S.; Seibel, N. L. National Cancer Institute Basket/Umbrella Clinical Trials: MATCH, LungMAP, and Beyond. Cancer J 2019, 25 (4), 272–281. https://doi.org/10.1097/PPO.0000000000000389.
13. Ravi, R.; Kesari, H. V. Novel Study Designs in Precision Medicine – Basket, Umbrella and Platform Trials. CRCEP 2022, 17 (2), 114–121. https://doi.org/10.2174/1574884716666210316114157.
14. Sedrak, M. S.; Ji, J.; Tiwari, A.; Mohile, S. G.; Dale, W.; Le-Rademacher, J. G. Clinical Trial Enrollment, Ineligibility, and Reasons for Decline in Older vs. Younger Patients With Cancer in the National Cancer Institute Community Oncology Research Program. JAMA Netw Open 2022, 5 (10), e2235714. https://doi.org/10.1001/jamanetworkopen.2022.35714.
15. Berger, M. F.; Mardis, E. R. The Emerging Clinical Relevance of Genomics in Cancer Medicine. Nat Rev Clin Oncol 2018, 15 (6), 353–365. https://doi.org/10.1038/s41571-018-0002-6.
16. Cheng, Y.; Tian, H. Current Development Status of MEK Inhibitors. Molecules 2017, 22 (10), E1551. https://doi.org/10.3390/molecules22101551.
17. Heckmann, J. M.; Thomas, R. K. A New Generation of Cancer Genome Diagnostics for Routine Clinical Use: Overcoming the Roadblocks to Personalized Cancer Medicine. Annals of Oncology 2015, 26 (9), 1830–1837. https://doi.org/10.1093/annonc/mdv184.
18. Baylin, S. B.; Jones, P. A. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 2016, 8 (9), a019505. https://doi.org/10.1101/cshperspect.a019505.